Skip to main content

Table 2 T5SS and RQLQ Overall Score at 4 Weeks

From: Persistent Allergic Rhinitis and the XPERT Study

Treatment Group N* Baseline/Mean (SD) After 4 Weeks of Treatment/Adjusted Mean (SEM)† Difference vs Placebo (95% CI)/Adjusted Mean P
RQLQ overall score      
   Placebo 252 3.06 (0.94) −1.01 (0.07)   
   Levocetirizine (5 mg) 257 3.04 (0.92) −1.49 (0.07) 0.48 (0.29-0.67) <0.001
T5SS      
   Placebo 271 8.90 (2.26) −2.40 (0.15)   
   Levocetirizine (5 mg) 276 9.02 (2.28) −3.54 (0.15) 1.14 (0.75-1.52) <0.001
  1. *Number of ITT patients with nonmissing values at baseline and under treatment.
  2. Mean change from baseline, adjusted for baseline score and country.